These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24851042)

  • 21. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
    Grunberger G
    Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Aletti R; Cheng-Lai A
    Cardiol Rev; 2012; 20(1):45-51. PubMed ID: 22143285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
    McGill JB; Barnett AH; Lewin AJ; Patel S; Neubacher D; von Eynatten M; Woerle HJ
    Diab Vasc Dis Res; 2014 Jan; 11(1):34-40. PubMed ID: 24169807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
    Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
    Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linagliptin: in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2011 Mar; 71(5):611-24. PubMed ID: 21443284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
    Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR; Swallow R; Dugi KA; Woerle HJ
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linagliptin use in older individuals with type 2 diabetes.
    Pratley RE
    Clin Interv Aging; 2014; 9():1109-14. PubMed ID: 25083132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2012 Feb; 67(2):91-7. PubMed ID: 22482239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
    McKeage K
    Drugs; 2014 Oct; 74(16):1927-1946. PubMed ID: 25297911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
    McGill JB; Sloan L; Newman J; Patel S; Sauce C; von Eynatten M; Woerle HJ
    Diabetes Care; 2013 Feb; 36(2):237-44. PubMed ID: 23033241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral Linagliptin (Trajenta)].
    Duh D; Tanret I
    J Pharm Belg; 2013 Mar; (1):41-3. PubMed ID: 23638612
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
    Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
    Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
    Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
    Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.
    Rungby J
    Expert Opin Investig Drugs; 2009 Jun; 18(6):835-8. PubMed ID: 19426127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.